Osteoblasts play key roles in the mechanisms of action of strontium ranelate

British Journal of Pharmacology

Volumn 157, Issue 7, 2009, Pages 1291-1300

  Brennan, T C ^a,b   Rybchyn, M S ^a,b   Green, W ^a,b   Atwa, S ^a,b   Conigrave, A D ^a   Mason, R S ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Bosch Institute   (Australia)

Author keywords

Alkaline phosphatase; Calcium sensing receptor; Human osteoblasts; OPG; RANKL; Runx2; Strontium ranelate

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM SENSING RECEPTOR; CASPASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SMALL INTERFERING RNA; STRONTIUM RANELATE; THYMIDINE; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL DIVISION; CELL STRESS; CELL SURVIVAL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANABOLIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; GENE KNOCKDOWN TECHNIQUES; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTORS, CALCIUM-SENSING; RNA, MESSENGER; RNA, SMALL INTERFERING; THIOPHENES;

EID: 70350304534     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00305.x     Document Type: Article

References (64)

1. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK et al. (2007). Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282: 27285-27297
2. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R (2004). Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 20: 548
3. Ammann P, Badoud I, Barraud S, Dayer R, Rizzoli R (2007). Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 22: 1419-1425
4. Anderson P, O'Loughlin P, May B, Morris H (2003). Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcriptase-polymerase chain reaction. J Mol Endocrinol 31: 123-132
5. Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux J-P et al. (2008). Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23: 215-222
6. Atkins GJ, Welldon KJ, Halbout P, Findlay DM (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporosis Int 20: 653-664
7. Boivin G, Deloffre P, Perrat B, Panczer G, Boudeulle M, Mauras Y et al. (1996). Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 11: 1302-1311
8. Bonewald LF (2004). Osteocyte biology: its implications for osteoporosis. J Musculoskelet Neuronal Interact 4: 101-104
9. Bonnelye E, Chabadel A, Saltel F, Jurdic P (2008). Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42: 129-138
10. Bradford M (1976). A rapid and sensitive for the quantitation of microgram quantitites of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
11. Brennan TC, Muir MM, Conigrave AD, Mason RS (2005). Functional responses of osteoblastic cells to stimulation by strontium. J Bone Miner Res 20: M196 (p S359)
12. Brennan TC, Rybchyn MS, Halbout P, Conigrave AD, Mason RS (2007). Strontium ranelate effects in human osteoblasts support its uncoupling effect on bone formation and bone resorption. J Bone Miner Res 22: M014
13. Brown E, Fuleihan Gel-H, Chen C, Kifor O (1990). A comparison of the effects of divalent and trivalent cations on parathyroid hormone release, 3′,5′-cyclic-adenosine monophosphate accumulation, and the levels of inositol phosphates in bovine parathyroid cells. [Published erratum appears in Endocrinology 1992 Aug. 131 (2): 862]. Endocrinology 127: 1064-1071
14. Brown EM (2003). Is the calcium receptor a molecular target for the actions of strontium on bone. Osteoporos Int 14: S25-S34
15. Brown EM, MacLeod RJ (2001). Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239-297
16. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A (2001). Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 29: 176-179
17. Bustin SA (2002). Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Endocrinol 29: 23-39
18. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie JP (1996). The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18: 517-523
19. Chang W, Tu C, Chen T-H, Bikle D, Shoback D (2008). the extracellular calcium-sensing receptor (CaSR) is a critical modulator of skeletal development. Sci Signal 1: ra1
20. Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM (2007). The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 74: 438-447
21. Choudhary S, Halbout P, Alander C, Raisz L, Pilbeam C (2007). Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins. J Bone Miner Res 22: 1002-1010
22. Colquhoun D (1971). Lectures on Biostatistics-An Introduction to Statistics with Applications in Biology and Medicine. Clarendon Press: Oxford
23. Coulombe J, Faure H, Robin B, Ruat M (2004). In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem Biophys Res Commun 323: 1184-1190
24. Dahl SG, Allain P, Marie PJ, Mauras Y, Boivin G, Ammann P et al. (2001). Incorporation and distribution of strontium in bone. Bone 28: 446-453
25. Delannoy P, Bazot D, Marie PJ (2002). Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 51: 906-911
26. Dennison E (1999). Epidemiology of glucocorticoid-induced osteoporosis. Osteoporos Int 9: S16
27. Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF et al. (2004). Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of cal-ciotropic hormones. Proc Natl Acad Sci 101: 5140-5145
28. Gu G, Mulari M, Peng Z, Hentunen TA, Väänänen HK (2005). Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. Biochem Biophys Res Commun 335: 1095-1101
29. Häuselmann HJ, Rizzoli R (2003). A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 14: 2-12
30. Hurtel AS, Mentaverri R, Wattel A, Kamel S, Brazier M (2007). Strontium ranelate and calcium exert cumulative effects on osteoclasts by activation of different intracellular signalling pathways, downstream of the calcium-sensing receptor. Calcif Tissue Int (Suppl. 1): P352-M
31. Hurtel AS, Mentaverri R, Caudrillier A, Cournarie F, Wattel A, Kamel S et al. (2008). The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis: new insights into the associated signalling pathways. J Biol Chem M801668200
32. Igarashi M, Kamiya N, Hasegawa M, Kasuya T, Takahashi T, Takagi M (2004). Inductive effects of dexamethasone on the gene expression of Cbfa1, osterix and bone matrix proteins during differentiation of cultured primary rat osteoblasts. J Mol Histol 35: 3-10
33. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999). Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104: 439-446
34. Karsenty G, Wagner EF (2002). Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2: 389-406
35. Karsenty G, Ducy P, Starbuck M, Priemel M, Shen J, Geoffroy V et al. (1999). Cbfa1 as a regulator of osteoblast differentiation and function. Bone 25: 107-108
36. Ke L, Chen Z, Yung W (2000). A reliability test of standard-based quantitative PCR: exogenous vs endogenous standards. Mol Cell Probes 14: 127-135
37. Khosla S (2001). Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050-5055
38. Kifor O, Diaz R, Butters R, Brown EM (1997). The Ca2+-Sensing receptor (CaR) activates phospholipases C, A(2) and Din bovine parathyroid and CaR-transfected, human embryonic kidney (HEK293) cells. J Bone Miner Res 12: 715-725
39. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L et al. (2001). Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104: 719-730
40. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteo-clast differentiation and activation. Cell 93: 165-176
41. Lowry OH (1955). Specific procedures. alkaline phosphatase. In: Pastan IH, (ed.). Micromethods for the Assay of Enymes. Academic Press: New York, pp. 265-371
42. McLarnon SJ, Holden D, Ward DT, Jones MN, Elliott AC, Riccardi D (2002). Aminoglycoside antibiotics induce pH-sensitive activation of the calcium-sensing receptor. Biochem Biophys Res Commun 297: 71-77
43. Mailland M, Waelchli R, Ruat M, Boddeke HGWM, Seuwen K (1997). Stimulation of cell proliferation by calcium and a calcimimetic compound. Endocrinology 138: 3601-3605
44. Marie P, Hott M (1986). Short-term effects of flouride and strontium on bone formation and resoption in the mouse. Metabolism 35: 547-551
45. Marie P, Hott M, Modrowski D, De Pollak C, Guillemain J, Deloffre P et al. (1993). An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8: 607-615
46. Marie PJ (2008). Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 473: 98-105
47. Marie PJ, Hott M (1986). Short-term effects of fluoride and strontium on bone formation and resorption in the mouse. Metabolism 35: 547-551
48. Marie PJ, Garber MT, Hott M, Miravet L (1985). Effect of low doses of stable strontium on bone metabolism in rats. Miner Electrolyte Metab 11: 5-13
49. Mentaverri R, Chattopadhyay N, Lemaire-Hurtel AS, Kamel S, Brazier M, Brown EM (2005). The effects of strontium ranelate on osteo-clasts are calcium-sensing receptor dependent. J Bone Miner Res 20: S309
50. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C et al. (2002a). Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87: 2060-2066
51. Meunier PJ, Roux C, Ortolani S, Badurski J, Kaufman JM, Spector T et al. (2002b). Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos Int 13: 521-522
52. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al. (2004a). The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459-468 (Pubitemid 38133766)
53. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD et al. (2004b). The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459-468 (Pubitemid 38133766)
54. Namkung-Matthai H, Seale JP, Brown K, Mason RS (1998). Comparative effects of anti-inflammatory corticosteroids in human bone-derived osteoblast-like cells. Eur Respir J 12: 1327-1333
55. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C (2002). Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 13: 925-931
56. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C et al. (2005). Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral psteoporosis (TROPOS) study. J Clin Endocrinol Metab 90: 2816-2822
57. Ruat M, Snowman AM, Hester LD, Snyder SH (1996). Cloned and expressed rat Ca2+-sensing receptor. J Biol Chem 271: 5972-5975
58. Sambrook PN, Hughes DR, Nelson AE, Robinson BG, Mason RS (2003). Osteocyte viability with glucocorticoid treatment: relation to his-tomorphometry. Ann Rheum Dis 62: 1215-1217
59. Sivagurunathan S, Muir M, Brennan TC, Seale JP, Mason RS (2005). Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 20: 390-398
60. Slater M, Patava J, Mason RS (1994a). Role of chondroitin sulfate glycosaminoglycans in mineralizing osteoblast-like cells: effects of hormonal manipulation. J Bone Miner Res 9: 161-169
61. Slater M, Patava J, Kingham K, Mason RS (1994b). Modulation of growth factor incorporation into ECM of human osteoblast-like cells in vitro by 17 beta-estradiol. Am J Physiol 267: E990-1001
62. Tricarico C, Pinzani P, Bianchi S, Paglierani M, Distante V, Pazzagli M et al. (2002). Quantitative real-time reverse transcription poly-merase chain reaction: normalization to rRNA or single housekeeping genes is inappropriate for human tissue biopsies. Anal Biochem 309: 293-300
63. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998). Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282
64. Zhu G, Chang Y, Zuo J, Dong X, Zhang M, Hu G et al. (2001). Fundine, a C-terminal truncated rat homologue of mouse prominin, is blood glucose-regulated and can up-regulate the expression of GAPDH. Biochem Biophys Res Commun 281: 951-956